Indication: Small Cell Carcinoma

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma

Patients wilth Lung Cancer

Sub-indication: Small cell: 3rd line or beyond; study drug RRx-001 along with Platinum Doublet or Platinum Doublet

Line of Therapy: 3rd line or beyond, small cell; prior platinum treatment

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: EpicentRx (formerly RadioRx)

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.